What is the impact of biomarkers on stroke rates for non-anticoagulated AF patients?
Recent studies in real-world cohorts do not support the clinical usefulness of biomarker-based scores over clinical risk scores such as the CHA2DS2-VASc score. There are few/no studies on non-anticoagulated AF patients, to ascertain the true impact of biomarkers on (non- anticoagulation treated) stroke rates. Current studies do not inform whether the biomarkers will discriminate/ identify low risk in lower/intermediate risk patients who are not anticoagulated. Rather than focus on identifying high risk, the focus should be on initially identifying low risk patients.